Bioanalytical
Pharma firm looks to parallel chromatography to speed development
Jun 25 2010
Using the parallel chromatography procedure, the pharma firm explains that it is able to double the capacity of its manufacturing line by running across multiple shifts.
On May 26th, ViroPharma disclosed that it had supplied Cinryze manufactured through the parallel chromatography process for use in patients with hereditary angioedema.
Now it has filed a Prior Approval Supplement with the US Food and Drug Administration to allow it to commercialise the drug manufactured through the industrial scale process.
The request hinges on industrial-scale production of the drug matching the quality of the previous scale in use.
ViroPharma says that it has the data to demonstrate this being the case and expects to see approval granted by the end of the year.
Cinryze is an injectible medicine which tackles hereditary angioedema by preventing painful attacks and helping to reduce the risk of swelling.
Digital Edition
Chromatography Today - Buyers' Guide 2022
October 2023
In This Edition Modern & Practical Applications - Accelerating ADC Development with Mass Spectrometry - Implementing High-Resolution Ion Mobility into Peptide Mapping Workflows Chromatogr...
View all digital editions
Events
Nov 12 2024 Tel Aviv, Israel
Nov 18 2024 Shanghai, China
Nov 18 2024 Plainsboro, NJ, USA
Nov 20 2024 Karachi, Pakistan
Jan 20 2025 Amsterdam, Netherlands